$MRK FDA Approves 2nd Biomarker-Based Indication for KEYTRUDA, Regardless of Tumor Type, for Tumor Mutational Burden-High Solid Tumors (TMB≥10 Mutations/Mb)
https://t.co/v3EESPkwiC

Simply amazing how Merck gets approval first again after what $BMY tried for TMB https://t.co/PO4PCDsO2T